Intranasal Influenza Vaccine in a Working Population
Open Access
- 1 April 2004
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 38 (7), 974-980
- https://doi.org/10.1086/386330
Abstract
In the present study, we assessed the incidence of adverse events and influenza-like symptoms in a working population in Switzerland that was vaccinated against influenza. A total of 12,582 individuals of working age (<65 years old) were offered a free influenza vaccine of their choice (injectable or intranasal vaccine) in October and November 2000. Of these individuals, 1600 were vaccinated against influenza. Ninety-seven percent of the vaccine recipients chose the intranasal vaccine, and 3% chose the injectable influenza vaccine. The incidence of influenza-like symptoms and side effects was 13% and 36%, respectively. Individuals who chose the intranasal vaccine were more likely to report side effects (OR, 3.23; 95% CI, 1.29–8.08). Facial paralysis was observed in 11 patients and was the most severe adverse event associated with the intranasal influenza vaccine. As a result of these adverse events, the intranasal vaccine was removed from the market in the fall of 2001.This publication has 19 references indexed in Scilit:
- Use of the Inactivated Intranasal Influenza Vaccine and the Risk of Bell's Palsy in SwitzerlandThe New England Journal of Medicine, 2004
- Estimating Deaths Due to Influenza and Respiratory Syncytial VirusJAMA, 2003
- Influenza virus infection in infancy and early childhoodPaediatric Respiratory Reviews, 2003
- Mortality Associated With Influenza and Respiratory Syncytial Virus in the United StatesJAMA, 2003
- Influenza: vaccination and treatmentEuropean Respiratory Journal, 2001
- Safety and Immunogenicity of Intranasally Administered Inactivated Trivalent Virosome‐Formulated Influenza Vaccine ContainingEscherichia coliHeat‐Labile Toxin as a Mucosal AdjuvantThe Journal of Infectious Diseases, 2000
- Impact of Respiratory Virus Infections on Persons With Chronic Underlying ConditionsJAMA, 2000
- Update on Influenza and Rhinovirus InfectionsAdvances in Experimental Medicine and Biology, 1999
- The Efficacy of Live Attenuated, Cold-Adapted, Trivalent, Intranasal Influenzavirus Vaccine in ChildrenThe New England Journal of Medicine, 1998
- Impact of influenza and respiratory syncytial virus on mortality in England and Wales from January 1975 to December 1990Epidemiology and Infection, 1996